IBT is a clinical stage pharmaceutical company with a vision to develop drugs influencing the infant microbiome, and thereby prevent or treat rare diseases affecting infants. IBT is currently developing IBP-9414 to prevent NEC in premature infants. IBP-9414 contains the active substance Lactobacillus reuteri, which is a co-evolved human bacterial strain naturally present in breast milk known to be anti-inflammatory, anti-pathogenic and beneficial to gut motility. The FDA granted IBT Orphan Drug Designation for Lactobacillus reuteri for the prevention of NEC in premature infants in 2013 and by the European Commission in 2015. IBT also received Rare Pediatric Disease Designation from FDA in 2016. In June 2016, IBT commenced the Safety and Tolerability study. In late 2017, the results demonstrated a similar safety and tolerability profile in the active group as in the placebo group. The pivotal Phase III study, the Connection study, commenced July 4, 2019.
Infant Bacterial Therapeutics (IBT) - NEC Prevention
Infant Bacterial Therapeutics - NEC Prevention
Bryggargatan 10
Stockholm
111 21
Sweden